文献速递糖尿病

达格列净联合沙格列汀治疗的2型糖尿病患者的临床参数、燃料氧化与葡萄糖动力学

Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
PubMed 文献 · Diabetes Care · 2020-07-21

56例2型糖尿病患者随机接受达格列净10 mg、达格列净/沙格列汀10/5 mg或安慰剂治疗16周,达格列净/沙格列汀组HbA1c降幅大于达格列净组和安慰剂组,部分因葡萄糖利用和氧化增加,但内源性葡萄糖生成矛盾性升高持续存在。

要点

  • 达格列净/沙格列汀组HbA1c降幅大于达格列净单药组和安慰剂组。
  • 达格列净单药治疗16周内源性葡萄糖生成升高,尽管空腹血糖降低。
  • 沙格列汀可防止胰岛素/胰高血糖素比值下降,但内源性葡萄糖生成升高持续。

核心结论

  • 在达格列净基础上加用沙格列汀较达格列净单药治疗血糖控制更优,部分因葡萄糖利用和氧化增加。
  • 沙格列汀可防止胰岛素/胰高血糖素比值下降,但内源性葡萄糖生成矛盾性升高持续存在,提示其他因素介导SGLT2i所致糖尿引起的内源性葡萄糖生成变化。

研究设计与样本

  • 随机对照研究,56例2型糖尿病患者(HbA1c 8.9 ± 0.2% [74 ± 2 mmol/mol])随机接受达格列净10 mg、达格列净/沙格列汀10/5 mg或安慰剂治疗16周。
  • 治疗前后测定基础内源性葡萄糖生成(3-3H-葡萄糖)、尿糖排泄、葡萄糖/脂质氧化、HbA1c及底物/激素水平。

主要发现

  • 第16周HbA1c降幅达格列净/沙格列汀组为-2.0 ± 0.3%,大于达格列净组的-1.4 ± 0.2%(P < 0.05),也大于安慰剂组的0.2 ± 0.2%。
  • 给药第1天,内源性葡萄糖生成(约2.40 mg/kg/min)在安慰剂组降低-0.44 ± 0.09 mg/kg/min(P < 0.05),在达格列净组和达格列净/沙格列汀组仅降低-0.21 ± 0.02 mg/kg/min(P < 0.05 vs. 安慰剂)。
  • 第16周,内源性葡萄糖生成升至2.67 ± 0.09 mg/kg/min(达格列净组)和2.61 ± 0.08 mg/kg/min(达格列净/沙格列汀组),尽管空腹血糖分别降低47和77 mg/dL,安慰剂组无变化。
  • 基线血浆游离脂肪酸在达格列净组升高40 µmol/L,在安慰剂组降低-110 µmol/L,在达格列净/沙格列汀组降低-90 µmol/L(P < 0.05,治疗前后比较)。
  • 达格列净组碳水化合物氧化率从1.1 ± 0.1降至0.7 ± 0.1 mg/kg/min,脂质氧化率从0.6 ± 0.1升至0.8 ± 0.1 mg/kg/min(P < 0.01);达格列净/沙格列汀组碳水化合物氧化(1.1 ± 0.1至0.9 ± 0.1 mg/kg/min)和脂质氧化(0.6 ± 0.1至0.7 ± 0.1 mg/kg/min)的转变减弱(P < 0.05)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the mechanisms responsible for improved glycemia with combined sodium-glucose cotransporter 2 inhibitor (SGLT2i) plus dipeptidyl peptidase 4 inhibitor therapy in type 2 diabetes. RESEARCH DESIGN AND METHODS: Fifty-six patients (HbA1c 8.9 ± 0.2% [74 ± 2 mmol/mol]) were randomized to dapagliflozin (DAPA) 10 mg, DAPA/saxagliptin (SAXA) 10/5 mg, or placebo (PCB) for 16 weeks. Basal endogenous glucose production (EGP) (3-3H-glucose), urinary glucose excretion, glucose/lipid oxidation, HbA1c, and substrate/hormone levels were determined before treatment (Pre-Tx) and after treatment (Post-Tx). RESULTS: At week 16, HbA1c decrease was greater (P < 0.05) in DAPA/SAXA (-2.0 ± 0.3%) vs. DAPA (-1.4 ± 0.2%) and greater than PCB (0.2 ± 0.2%). Day 1 of drug administration, EGP (∼2.40 mg/kg/min) decreased by -0.44 ± 0.09 mg/kg/min in PCB (P < 0.05) but only by -0.21 ± 0.02 mg/kg/min in DAPA and DAPA/SAXA (P < 0.05 vs. PCB). At week 16, EGP increased to 2.67 ± 0.09 mg/kg/min (DAPA) and 2.61 ± 0.08 mg/kg/min (DAPA/SAXA), despite reductions in fasting plasma glucose by 47 and 77 mg/dL, respectively, and no changes in PCB. Baseline plasma free fatty acids rose by 40 µmol/L with DAPA but declined by -110 with PCB and -90 µmol/L with DAPA/SAXA (P < 0.05, Pre-Tx vs. Post-Tx). In DAPA, carbohydrate oxidation rates decreased from 1.1 ± 0.1 to 0.7 ± 0.1 mg/kg/min, whereas lipid oxidation rates increased from 0.6 ± 0.1 to 0.8 ± 0.1 mg/kg/min (P < 0.01). In DAPA/SAXA, the shift in carbohydrate (1.1 ± 0.1 to 0.9 ± 0.1 mg/kg/min) and lipid (0.6 ± 0.1 to 0.7 ± 0.1 mg/kg/min) oxidation was attenuated (P < 0.05). CONCLUSIONS: The addition of SAXA to DAPA resulted in superior glycemic control compared with DAPA monotherapy partly because of increased glucose utilization and oxidation. Although the decrease in insulin/glucagon ratio was prevented by SAXA, EGP paradoxical elevation persisted, indicating that other factors mediate EGP changes in response to SGLT2i-induced glucosuria.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Qin Y, Adams J, Solis-Herrera C, et al. Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin. Diabetes Care. 2020. PMID: 32694214. doi:10.2337/dc19-1993

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。